Advertisement

Topics

Companies Related to "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury" [Most Relevant Company Matches] RSS

01:10 EST 22nd February 2019 | BioPortfolio

Here are the most relevant search results for "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury" found in our extensive corporate database of over 50,000 company records.

Showing "Deferiprone Prevention Contrast Induced Acute Kidney Injury" Companies 1–25 of 1,600+

Extremely Relevant

Ischemix, Inc.

Ischemix is a privately-held, clinical-stage pharmaceutical company developing novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions. The initial focus of the Company is the prevention of acute kidney injury and cardiac injury in patients undergoing cardiac catheterization procedures. Ischemix’ lead product...


CorMedix Inc.

CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, tr...

Thrasos Therapeutics

Thrasos TherapeuticsTM is a private, clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The Company is advancing therapeutic programs, led by THR-184, for renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). Thrasos’...


Thrasos, Inc.

Thrasos is a private, clinical stage, bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The Company has advanced two compounds, THR-184 and THR-123, into development for Acute Kidney Injury (AKI) and Chronic Kidney Injury (CKD), respectively, and initiated Phase 1 cli...

Osprey Medical Inc.

Osprey Medical's core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker IDI Heart and Diabetes Institute. Osprey is focused on improving patients’ quality of life by protecting those with chronic kidney disease from contrast induced nephropathy (CIN) and preventing limb amputation in diabetic patients with advanced ...

Relevant

AM‐Pharma B.V.

AM‐Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. AM‐Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and ...

AM-Pharma B.V.

AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. AM-Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a P...

Astute Medical, Inc.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community and hospital acquired acute conditions that require rapid diagnosis and risk assessment. The Company's current areas of interest include abdominal ...

A1M Pharma

A1M Pharma develops a diagnostic method and a novel treatment for the damaging effects of pre-eclampsia, a condition that affects around 10 million pregnant women worldwide. This disorder is responsible for 76,000 maternal and 500,000 infant deaths each year. It is also the cause of 15 per cent of all premature births. Currently, there is no predictive diagnostic method or treatment for impairme...

MedaSorb Technologies

MedaSorb Technologies (“MedaSorb” or the “Company) has developed a new platform technology that efficiently removes toxic compounds from the bloodstream. Current state-of-the-art blood purification techniques are not designed for this purpose and are inefficient at removing these toxins. The Company’s products, which incorporate a proprietary adsorbent polymer technology, are known medical...

PLC Systems Inc.

PLC Medical Systems, Inc., the operating subsidiary of PLC Systems Inc., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's lead product, RenalGuard®, significantly reduces the onset of CIN in at-risk patients undergoing certain cardiac and vascular imaging procedures. CIN is a form of acute kidney...

RenalGuard Solutions, Inc.

RenalGuard measures a patient's urine output and automatically infuses hydration fluid based on that urine output. The system is designed to induce high urine rates, which have been shown to protect the kidney from a range of insults. A number of studies have demonstrated RenalGuard's ability to protect patients from AKI following catheterization procedure...

Kidney Research UK

Kidney disease is not, as commonly thought, a disease that affects only the elderly - it can happen at any age. Treatment options include a transplant - for which there is a waiting list or a life on dialysis, a life sustaining treatment - but which can severely restrict daily life.Founded in 1961, Kidney Research UK is the leading UK charity funding research that focuses on the prevention, treatm...

National Kidney Foundation Singapore

The World Kidney Fund was established as an international fund by the National Kidney Foundation Singapore to help kidney patients in developing countries who have little or no access to renal healthcare facilities. Through this fund, training programmes are developed to empower non-profit kidney organisations to establish sustainable life-saving kidney healthcare programmes. The World Kidney Fun...

Nephrocor

Nephrocor™ is an anatomic pathology laboratory exclusively serving nephrologists throughout the U.S. In addition to providing RenalVysion™, a proprietary non-invasive test for kidney injury, Nephrocor offers renal biopsy and chemistry profiles for the diagnosis, treatment and management of kidney diseases. Nephrocor’s state-of-the-art laboratory is located in Richmond, Virginia.

ART Medical

ART Medical, based out of Israel and Palo Alto, was founded by the CEO Liron Elia in 2009. The company offers a range of products that optimize enteral feeding as well as detect and prevent aspiration pneumonia, VAP and Acute Kidney Injury in intubated patients. The technology has received FDA approval and is now in the final processes of clinical trials. ...

Promedior, Inc.

Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and gr...

Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a world leader in discovery and development of novel small interfering RNA, or siRNA, therapeutics for unmet medical needs. RNA interference is a biological process in which RNA molecules regulate expression of targeted genes. Quark’s fully integrated drug discovery and development platform spans the process from therape...

Osprey Medical, Inc.

Osprey Medical is a privately held company located in Eden Prairie, Minnesota. The Company is dedicated to the treatment and prevention of ailments originating from the inter-related functioning of the heart and kidneys with a primary focus on CIN. The Company’s CINCOR™ Contrast Removal System is a catheter based system that is designed to remove ...

Remedy Pharmaceuticals, Inc.

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury. RP-1127 has not yet been approved for use by the FDA.

National Kidney Foundation

The National Kidney Foundation, with offices throughout the country, is dedicated to preventing and treating kidney and urinary tract diseases, improving the health and well being of individuals and families affected by these diseases and increasing availability of all organs for transplantation. More at www.kidney.org.

RenaMed Biologics, Inc

RenaMed Biologics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. RenaMed’s products are designed to dramatically improve the clinical outcome and cost of care for patients suffering from Acute Renal Failure and additional indications where kidney function is compromised...

Heron Therapeutics, Inc.

Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that nee...

LoveYourBrain Foundation

LoveYourBrain Foundation is a non-profit organization that aims to improve the quality of life for people affected by brain injury. We are a growing family of like minded individuals who believe that the brain is our most important piece of equipment. Our message—LoveYourBrain—embodies our positive approach to brain injury prevention, recovery, a...

NephRx Corporation

NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis. Lead product NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical dev...


More From BioPortfolio on "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks